CN1711086A - 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂 - Google Patents

用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂 Download PDF

Info

Publication number
CN1711086A
CN1711086A CNA2003801029350A CN200380102935A CN1711086A CN 1711086 A CN1711086 A CN 1711086A CN A2003801029350 A CNA2003801029350 A CN A2003801029350A CN 200380102935 A CN200380102935 A CN 200380102935A CN 1711086 A CN1711086 A CN 1711086A
Authority
CN
China
Prior art keywords
disease
retina
vol
glaucoma
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801029350A
Other languages
English (en)
Chinese (zh)
Inventor
P·E·黑尔贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of CN1711086A publication Critical patent/CN1711086A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2003801029350A 2002-11-12 2003-10-27 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂 Pending CN1711086A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42557602P 2002-11-12 2002-11-12
US60/425,576 2002-11-12

Publications (1)

Publication Number Publication Date
CN1711086A true CN1711086A (zh) 2005-12-21

Family

ID=32313019

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801029350A Pending CN1711086A (zh) 2002-11-12 2003-10-27 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂

Country Status (12)

Country Link
US (2) US20040092431A1 (enExample)
EP (1) EP1562592A4 (enExample)
JP (1) JP2006508120A (enExample)
KR (1) KR20050074547A (enExample)
CN (1) CN1711086A (enExample)
AU (1) AU2003286686B2 (enExample)
BR (1) BR0316163A (enExample)
CA (1) CA2504226A1 (enExample)
MX (1) MXPA05004738A (enExample)
RU (1) RU2324483C2 (enExample)
WO (1) WO2004043348A2 (enExample)
ZA (1) ZA200503230B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107362148A (zh) * 2017-07-27 2017-11-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CN116348103A (zh) * 2020-06-11 2023-06-27 纽约市哥伦比亚大学理事会 用于用组蛋白脱乙酰酶(hdac)抑制剂曲古抑菌素a及其衍生物预防和治疗近视的方法和组合物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2504460A1 (en) * 2002-11-12 2004-05-27 Peter G. Klimko Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
CN1711086A (zh) * 2002-11-12 2005-12-21 爱尔康公司 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
GB2417682A (en) * 2004-08-18 2006-03-08 Univ East Anglia Histone deacetylse inhibitor for treating connective tissue disorders
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006272497B2 (en) * 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
CN101646651A (zh) 2007-03-28 2010-02-10 参天制药株式会社 具有脲结构的新型吡啶羧酸（2-氨基苯基）酰胺衍生物
JP2008266321A (ja) * 2007-03-28 2008-11-06 Santen Pharmaceut Co Ltd フェニレンジアミン誘導体を有効成分とする眼圧下降剤
CA2680838A1 (en) * 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
US8198271B2 (en) 2008-05-23 2012-06-12 Santen Pharmaceutical Co., Ltd. Thiophenediamine derivative having urea structure
PT2575467T (pt) * 2010-05-27 2016-10-14 Univ Colorado Regents Compostos macrocíclicos úteis como inibidores de histona desacetilases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2213504T1 (es) * 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
JP2003520183A (ja) * 1997-10-06 2003-07-02 アメリカン・サイアナミド・カンパニー マトリクス金属プロテイナーゼおよびｔａｃｅ阻害薬としてのオルト−スルホンアミド二環式ヘテロアリールヒドロキサム酸の製造および使用
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
JP2004516328A (ja) * 2000-12-22 2004-06-03 ヒャン ウー リー アピシジン誘導体、その合成方法、及び該誘導体を含む抗癌剤組成物
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
CN1711086A (zh) * 2002-11-12 2005-12-21 爱尔康公司 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂
US8034768B2 (en) * 2007-06-22 2011-10-11 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107362148A (zh) * 2017-07-27 2017-11-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CN116348103A (zh) * 2020-06-11 2023-06-27 纽约市哥伦比亚大学理事会 用于用组蛋白脱乙酰酶(hdac)抑制剂曲古抑菌素a及其衍生物预防和治疗近视的方法和组合物

Also Published As

Publication number Publication date
AU2003286686A1 (en) 2004-06-03
US20070088045A1 (en) 2007-04-19
ZA200503230B (en) 2006-06-28
EP1562592A2 (en) 2005-08-17
CA2504226A1 (en) 2004-05-27
BR0316163A (pt) 2005-09-27
JP2006508120A (ja) 2006-03-09
WO2004043348A2 (en) 2004-05-27
RU2005118108A (ru) 2006-01-20
US20040092431A1 (en) 2004-05-13
RU2324483C2 (ru) 2008-05-20
EP1562592A4 (en) 2009-01-21
AU2003286686B2 (en) 2009-07-16
WO2004043348A3 (en) 2004-07-15
KR20050074547A (ko) 2005-07-18
MXPA05004738A (es) 2005-08-03

Similar Documents

Publication Publication Date Title
CN1711086A (zh) 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂
US20080004311A1 (en) Histone deacetylase inhibitors for treating degenerative diseases of the eye
CA2496797C (en) Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
JP2023026512A (ja) 緑内障予防又は治療のための薬物療法
CA2399985A1 (en) Compounds with 5-ht activity useful for controlling visual field loss
JP2006508120A5 (enExample)
US5438060A (en) Method of reducing elevated intraocular pressure
JP2001508035A (ja) 炭酸脱水酵素阻害薬及びキサンタンガムを含有する眼科用組成物
JP2010215667A (ja) 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
KR100499903B1 (ko) 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제
US5236951A (en) Pharmaceutical compositions for the treatment of ocular disorders
Willis et al. Effects of topical administration of 0.005% latanoprost solution on eyes of clinically normal horses
US20120316143A1 (en) Ophthalmic composition
US5308849A (en) Method of reducing elevated intraocular pressure
JPWO2004004738A1 (ja) 角結膜上皮細胞障害治療薬又は予防薬
JPH08231400A (ja) イフェンプロジルを必須成分とする眼圧降下剤
US20030119846A1 (en) Compounds with 5-ht activity useful for controlling visual field loss
Woodward et al. Overview: Recent Developments in Glaucoma Therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication